Table 3.
Radiologic response rate in all 133 patients (analysed all 159 treatment combinations) and in the 115 patients that only received one lanreotide combination
| All patients | All treatment combinations | Everolimus + lanreotide | Sunitinib + lanreotide |
|---|---|---|---|
| N = 159 a | n = 73 | n = 61 | |
| Tumour response (%) | |||
| Complete response | 1 (0.6) | 0 | 1 (1.6) |
| Partial response | 22 (13.8) | 11 (15.1) | 9 (14.8) |
| Stable disease | 113 (71.1) | 49 (67.0) | 42 (68.9) |
| Progressive disease | 13 (8.2) | 9 (12.3) | 3 (4.9) |
| Not evaluated | 10 (6.2) | 4 (5.5) | 6 (9.8) |
| Patients that received only one lanreotide combination | One treatment combination | ||
| n = 115 | n = 57 | n = 50 | |
| Tumour response (%) | |||
| Complete response | 1 (0.9) | 0 | 1 (2.0) |
| Partial response | 20 (17.4) | 10 (17.5) | 8 (16) |
| Stable disease | 74 (64.3) | 35 (61.5) | 34 (68.0) |
| Progressive disease | 11 (9.6) | 8 (14.0) | 2 (4.0) |
| Not evaluated | 9 (7.8) | 4 (7.0) | 5 (10) |
aThe denominator is the total number of treatment combinations in 133 patients analysed